Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-2325a in Netherton Syndrome
2022-502853-32-00Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2023
- Modality
- Gene Therapies, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Netherton syndrome (NS) comparing DS-2325a with Placebo (2 arms). Primary endpoint: Safety endpoints. Started Jul 2023; status: completed.
02
Drugs
DS-2325a
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on 2022-502853-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502853-32-00.